The medical technology company is in the midst of commercializing sugarBEAT, a non-invasive and flexible continuous glucose monitor (CGM) for diabetes management.
In a statement, the Loughborough, England-based company said its CEO will provide insights into its head-to-head study with a major existing glucose monitoring solution with the goal of positioning sugarBEAT as an alternative to expensive and invasive continuous glucose monitors.
Nemaura has several studies planned over the course of this year designed to demonstrate the effectiveness of sugarBEAT to increase Time-In-Range, thus reducing Hemoglobin A1C with intermittent use over a few non-consecutive days per week or month.
Initial results from studies comparing the various market-leading CGM devices indicates sugarBEAT’s accuracy is on par with the major incumbent invasive CGM sensors, using single finger-stick blood glucose meter calibration in real-life settings, according to Nemaura.
CGMs are big business internationally, with the global total addressable market for CGMs estimated at $82 billion per year. The figure consists of $12.7 billion for Type 1 insulin users, $38 billion for Type 2 insulin users and $31.4 billion for Type 2 non-insulin users, which make up 80% of people with diabetes. The numbers exclude the prediabetes population which is estimated to be nearly three times as large as the diabetes population, according to data provided by Nemaura.
The firm is prioritizing launch plans in the US and is considering various options to expedite the launch, including possibly partnering with multinational companies.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas